With a strong interdisciplinary foundation and decades of scientific excellence, the University of Ljubljana brings valuable expertise to the IFIGENEIA consortium, contributing to the project’s vision of advancing next-generation radioisotope technologies.
The University of Ljubljana is Slovenia’s largest and most prominent educational and research institution, comprising 26 faculties and nearly 7,000 staff members dedicated to advancing knowledge and innovation. Renowned for its high-quality study programs across diverse fields, including natural sciences, medicine, and engineering, the university fosters both interdisciplinary and multidisciplinary education through collaborations with leading international institutions. Among its faculties, the Faculty of Medicine stands out as Slovenia’s leading centre for medical and dental education, biomedical research, and healthcare diagnostics. Actively engaged in numerous domestic, European, and international research collaborations, it plays an essential role in advancing medical science and clinical practice.
For the IFIGENEIA project, selected experts from the field of nuclear medicine, particularly those focusing on radiopharmacy and translational research, have joined the faculty’s research team, further strengthening its capacity for advanced interdisciplinary collaboration. Within the IFIGENEIA project, the University of Ljubljana contributes its specialised expertise by leading WP4: Radioisotope Production and Radiopharmaceuticals, as well as leading two tasks within WP4: Task 4.2 Identify Best Isotopes for Production with LINAC and Task 4.3 Investigate Best Ligands for Development within the Excellence Hub. Through its strong background in nuclear medicine, translational research, and radiopharmacy, the university supports the development of next-generation radionuclides and radiopharmaceuticals essential for advancing healthcare innovations across Europe.
